rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jack Kaye

Director

Company insider

Files Form 4 as: Director, uniQure; Director, Dyadic International; Director, Keryx Biopharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
135
Buys
2
Sells
17
Bought
$30K
Sold
$4.7M
Companies
3
Companies where not an officer
3
First trade
19 Jun 2007
Last trade
30 Jun 2026
Last filed
2 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
QURE uniQureDirector · Biotechnology · last 30 Jun 20260 buys · 15 sells
DYAI Dyadic InternationalDirector · Biotechnology · last 2 Jan 20260 buys · 0 sells
Keryx BiopharmaceuticalsDirector · last 17 Jun 20152 buys · 2 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
40Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Code M$152K4,107 at $37.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Sold$191K4,107 at $46.49filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Code M$344K17,060 at $20.18filing
30 Jun 2026filed 2 Jul 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—4,107 at $0.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—17,060 at $0.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Sold$792K17,060 at $46.43filing
30 Jun 2026filed 2 Jul 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—4,107 at $0.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—17,060 at $0.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Code M$152K4,107 at $37.00filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Sold$191K4,107 at $46.49filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Code M$344K17,060 at $20.18filing
30 Jun 2026filed 2 Jul 2026QURE uniQureBiotechnologySEC FORM 4 Sold$792K17,060 at $46.43filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$168K5,295 at $31.71filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$225K5,295 at $42.57filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—5,295 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—5,295 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$168K5,295 at $31.71filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$225K5,295 at $42.57filing
11 Jun 2026filed 12 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$54K1,993 at $27.06filing
11 Jun 2026filed 12 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$54K1,993 at $27.06filing

Sectors

Health Care15
Not placed4

Buys in green, sells in red, by the company’s sector.

Related people

Francisco Trust under agreement dated February 28, 199610% owner · 10% owner at Dyadic International, filing Form 4 there in the last year
Matthew C. KapustaCEO, Managing Director · CEO, Managing Director at uniQure, filing Form 4 there in the last year
Walid Abi-SaabChief Medical Officer · Chief Medical Officer at uniQure, filing Form 4 there in the last year
Madhavan BalachandranDirector · Director at uniQure, filing Form 4 there in the last year
Jeannette PottsChief Legal Officer · Chief Legal Officer at uniQure, filing Form 4 there in the last year